Related references
Note: Only part of the references are listed.Predictions of diabetes complications and mortality using hba1c variability: a 10-year observational cohort study
Sharen Lee et al.
ACTA DIABETOLOGICA (2021)
Proton pump inhibitor or famotidine use and severe COVID-19 disease: a propensity score-matched territory-wide study
Jiandong Zhou et al.
GUT (2021)
Chronic kidney disease progression among patients with type 2 diabetes identified in US administrative claims: a population cohort study
Csaba P. Kovesdy et al.
CLINICAL KIDNEY JOURNAL (2021)
Beneficial effects of dipeptidyl peptidase-4 inhibitors in diabetic Parkinson's disease
Seong Ho Jeong et al.
BRAIN (2021)
The Association Between Second-Line Oral Antihyperglycemic Medication on Types of Dementia in Type 2 Diabetes: A Nationwide Real-World Longitudinal Study
Won Jun Kim et al.
JOURNAL OF ALZHEIMERS DISEASE (2021)
Anticoagulant or antiplatelet use and severe COVID-19 disease: A propensity score-matched territory-wide study
Jiandong Zhou et al.
PHARMACOLOGICAL RESEARCH (2021)
Glycemic and lipid variability for predicting complications and mortality in diabetes mellitus using machine learning
Sharen Lee et al.
BMC ENDOCRINE DISORDERS (2021)
Cardiovascular and Renal Outcomes in Patients with Type-2 Diabetes and Chronic Kidney Disease Identified in a United States Administrative Claims Database: A Population Cohort Study
Kerstin Folkerts et al.
NEPHRON (2021)
Understanding the links between cardiovascular disease and Parkinson's disease
Judy Potashkin et al.
MOVEMENT DISORDERS (2020)
The dipeptidyl peptidase-4 inhibitor, linagliptin, improves cognitive impairment in streptozotocin-induced diabetic mice by inhibiting oxidative stress and microglial activation
Makoto Ide et al.
PLOS ONE (2020)
Cerebral microvascular complications of type 2 diabetes: stroke, cognitive dysfunction, and depression
Thomas T. van Sloten et al.
LANCET DIABETES & ENDOCRINOLOGY (2020)
Type 3 Diabetes and Its Role Implications in Alzheimer's Disease
Thuy Trang Nguyen et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
The Association Between Type 2 Diabetes Mellitus and Parkinson's Disease
Julia L. Y. Cheong et al.
JOURNAL OF PARKINSONS DISEASE (2020)
Impact of antidiabetic agents on dementia risk: A Bayesian network meta-analysis
Jian-Bo Zhou et al.
METABOLISM-CLINICAL AND EXPERIMENTAL (2020)
Relationships between memory decline and the use of metformin or DPP4 inhibitors in people with type 2 diabetes with normal cognition or Alzheimer's disease, and the role APOE carrier status
Che-Yuan Wu et al.
ALZHEIMERS & DEMENTIA (2020)
Diabetes medications and risk of Parkinson's disease: a cohort study of patients with diabetes
Ruth Brauer et al.
BRAIN (2020)
Effects of an SGLT2 inhibitor on cognition in diabetes involving amelioration of deep cortical cerebral blood flow autoregulation and pericyte function
Shaoxun Wang et al.
Alzheimers & Dementia (2020)
Perspective of SGLT2 Inhibition in Treatment of Conditions Connected to Neuronal Loss: Focus on Alzheimer's Disease and Ischemia-Related Brain Injury
Michal Wicinski et al.
PHARMACEUTICALS (2020)
Durability of glycaemic control with dapagliflozin, an SGLT2 inhibitor, compared with saxagliptin, a DPP4 inhibitor, in patients with inadequately controlled type 2 diabetes
Clifford J. Bailey et al.
DIABETES OBESITY & METABOLISM (2019)
Oral diabetes medication and risk of dementia in elderly patients with type 2 diabetes
Ju Young Kim et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2019)
Glycemic Control is Related to Cognitive Dysfunction in Elderly People with Type 2 Diabetes Mellitus in a Rural Chinese Population
Shuling Liu et al.
CURRENT ALZHEIMER RESEARCH (2019)
Antidiabetic medication and risk of dementia in patients with type 2 diabetes: a nested case control study
Ida Kim Wium-Andersen et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2019)
DPP-4 inhibitor improves learning and memory deficits and AD-like neurodegeneration by modulating the GLP-1 signaling
Shuyi Chen et al.
NEUROPHARMACOLOGY (2019)
Risk of Dementia in Older Patients with Type 2 Diabetes on Dipeptidyl-Peptidase IV Inhibitors Versus Sulfonylureas: A Real-World Population-Based Cohort Study
Young-Gun Kim et al.
JOURNAL OF CLINICAL MEDICINE (2019)
HbA1c, diabetes and cognitive decline: the English Longitudinal Study of Ageing
Fanfan Zheng et al.
DIABETOLOGIA (2018)
Depressive Symptoms, Co-Morbidities, and Glycemic Control in Hong Kong Chinese Elderly Patients With Type 2 Diabetes Mellitus
Annie C. H. Fung et al.
FRONTIERS IN ENDOCRINOLOGY (2018)
12-month effects of incretins versus SGLT2-Inhibitors on cognitive performance and metabolic profile. A randomized clinical trial in the elderly with Type-2 diabetes mellitus
Simone Perna et al.
CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS (2018)
Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease
Jayasankar Kosaraju et al.
MOLECULAR NEUROBIOLOGY (2017)
SGLT2-inhibitor and DPP-4 inhibitor improve brain function via attenuating mitochondrial dysfunction, insulin resistance, inflammation, and apoptosis in HFD-induced obese rats
Piangkwan Sa-nguanmoo et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2017)
Influence of Epidemiologic and Patient Behavior-Related Predictors on Amputation Rates in Diabetic Patients: Systematic Review and Meta-Analysis
Yong Shin Jin et al.
INTERNATIONAL JOURNAL OF LOWER EXTREMITY WOUNDS (2017)
The effects of sitagliptin, a DPP-4 inhibitor, on cognitive functions in elderly diabetic patients with or without Alzheimer's disease
Ahmet Turan Isik et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2017)
Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal
Ramesh Kandimalla et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2017)
Cognitive Dysfunction in Older Adults With Diabetes: What a Clinician Needs to Know
Medha N. Munshi
DIABETES CARE (2017)
Forxiga (dapagliflozin): Plausible role in the treatment of diabetes-associated neurological disorders
Sibhghatulla Shaikh et al.
BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY (2016)
Diabetes and Alzheimer's disease crosstalk
David Baglietto-Vargas et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2016)
Cognitive impairment in Parkinson's disease and dementia with Lewy bodies
Dag Aarsland
PARKINSONISM & RELATED DISORDERS (2016)
Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies
Peter C. Austin et al.
STATISTICS IN MEDICINE (2015)
Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis
Lana Pinto et al.
Diabetology & Metabolic Syndrome (2015)
Glycemic control with empagliflozin, a novel selective SGLT2 inhibitor, ameliorates cardiovascular injury and cognitive dysfunction in obese and type 2 diabetic mice
Bowen Lin et al.
CARDIOVASCULAR DIABETOLOGY (2014)
Dipeptidyl Peptidase-4 Inhibitors Have Protective Effect on Cognitive Impairment in Aged Diabetic Patients With Mild Cognitive Impairment
Maria Rosaria Rizzo et al.
JOURNALS OF GERONTOLOGY SERIES A-BIOLOGICAL SCIENCES AND MEDICAL SCIENCES (2014)
Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease
Jayasankar Kosaraju et al.
JOURNAL OF PHARMACY AND PHARMACOLOGY (2013)
Saxagliptin: A dipeptidyl peptidase-4 inhibitor ameliorates streptozotocin induced Alzheimer's disease
Jayasankar Kosaraju et al.
NEUROPHARMACOLOGY (2013)
Glucose Levels and Risk of Dementia
Jan T. Kielstein
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Diabetes and Risk of Parkinson's Disease
Qun Xu et al.
DIABETES CARE (2011)
An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies
Peter C. Austin
MULTIVARIATE BEHAVIORAL RESEARCH (2011)
Long-term inhibition of dipeptidyl peptidase-4 in Alzheimer's prone mice
Michele D'Amico et al.
EXPERIMENTAL GERONTOLOGY (2010)
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
N. Sarwar et al.
LANCET (2010)
High-dimensional Propensity Score Adjustment in Studies of Treatment Effects Using Health Care Claims Data
Sebastian Schneeweiss et al.
EPIDEMIOLOGY (2009)
Cognitive dysfunction and diabetes mellitus
Christopher T. Kodl et al.
ENDOCRINE REVIEWS (2008)
Type 2 diabetes and the risk of Parkinson's disease
Gang Hu et al.
DIABETES CARE (2007)
Cardiovascular disease and Alzheimer's disease: common links
M. J. Stampfer
JOURNAL OF INTERNAL MEDICINE (2006)
Cognitive decline and dementia in diabetes - systematic overview of prospective observational studies
T Cukierman et al.
DIABETOLOGIA (2005)
Obesity and vascular risk factors at midlife and the risk of dementia and Alzheimer disease
M Kivipelto et al.
ARCHIVES OF NEUROLOGY (2005)
Dementia with Lewy bodies and Parkinson's disease
IG McKeith et al.
PARKINSONISM & RELATED DISORDERS (2004)
Share Paper
